{
    "clinical_study": {
        "@rank": "9816", 
        "arm_group": [
            {
                "arm_group_label": "Healthy control subjects", 
                "description": "Characterize the baseline PA signals produced by the in vivo PAFC prototype device in healthy volunteers or Develop Standard Curves for the ex vivo CTC assays."
            }, 
            {
                "arm_group_label": "Advanced-Stage Melanoma", 
                "description": "To validate the in vivo PAFC method of melanoma CTC detection, we will use the PAFC-based prototype device to noninvasively determine CTC concentrations in the blood of subjects who have advanced-stage (Stage III or Stage IV)melanoma, and we will also use current ex vivo methods to determine the CTC concentration in samples of blood drawn from the same subjects."
            }, 
            {
                "arm_group_label": "Early-Stage Melanoma", 
                "description": "To determine whether in vivo PAFC can detect melanoma CTCs at concentrations below the detection limits of the ex vivo methods, we will use the PAFC-based prototype device to noninvasively detect CTCs in the blood of subjects who have early-stage (Stages I or II) melanoma, and we will also use current ex vivo methods to detect CTCs in samples of blood drawn from the same subjects."
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this clinical trial is to determine whether a Photoacoustic flow cytometry\n      (PAFC)-based prototype device can detect circulating tumor cells (CTCs) in the blood of\n      melanoma patients in vivo, in real time, and do so at detection limits at least one order of\n      magnitude below the detection limits of currently existing ex vivo methods."
        }, 
        "brief_title": "In Vivo Real-time Detection of Circulating Melanoma Cells", 
        "condition": "Melanoma", 
        "condition_browse": {
            "mesh_term": "Melanoma"
        }, 
        "detailed_description": {
            "textblock": "Study Population: Approximately 80 subjects will be consented in order to achieve an\n      enrollment goal of 75 subjects at this institution in three cohorts as follows:\n\n        1. Cohort #1 will consist of fifteen healthy control subjects, ten of whom will be\n           Caucasian and five of whom will be African-American. Subjects in cohort #1 will be used\n           to address the calibration goal of Specific Aim #1.\n\n        2. Cohort #2 will consist of 30 subjects who have advanced-stage melanoma will be\n           recruited from the Medical Oncology clinic at UAMS, where advanced stages are defined\n           as Stages III or IV. Subjects in cohort #2 will be used to address the validation goal\n           of Specific Aim #2. Approximately half of the 30 advanced-stage subjects will be Stage\n           III and the other half will be Stage IV.\n\n        3. Cohort #3 will consist of 30 subjects with early-stage melanoma will be recruited from\n           the Surgical Oncology clinic at UAMS, where early stages are defined as Stages I or II.\n\n      Subjects in cohort #3 will be used to address the detection goal of Specific Aim #3.\n      Approximately 10 of the 30 early-stage subjects will be Stage I and approximately 20 will be\n      Stage II."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 18 to 80 years\n\n          -  Histological documented diagnosis of melanoma\n\n          -  Signed informed consent form approved by the University of Arkansas for   Medical\n             Sciences (UAMS) Institutional Review Board (IRB)\n\n          -  Must be able to sit still for 90 minutes\n\n        Exclusion Criteria:\n\n          -  Active infection\n\n          -  Current and significant medical or surgical condition as determined by the\n             Investigator\n\n          -  Diagnosis or evidence of organic brain syndrome\n\n          -  Pregnancy or breastfeeding"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Expect to consent approximately 80 subjects in order to achieve an enrollment goal of 75\n        subjects at this institution in three cohorts."
            }
        }, 
        "enrollment": {
            "#text": "75", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01776905", 
            "org_study_id": "133965"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Melanoma", 
            "Cancer"
        ], 
        "lastchanged_date": "January 24, 2014", 
        "location": {
            "contact": {
                "email": "ZharovVladimirP@uams.edu", 
                "last_name": "Vladimir Zharov, PhD", 
                "phone": "501-603-1213"
            }, 
            "facility": {
                "address": {
                    "city": "Little Rock", 
                    "country": "United States", 
                    "state": "Arkansas", 
                    "zip": "72205"
                }, 
                "name": "University of Arkansas for Medical Sciences"
            }, 
            "investigator": [
                {
                    "last_name": "Laura Hutchins, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Vladimir Zharov, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Ekaterina Galanzha, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Sara Shalin, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "3", 
        "official_title": "In Vivo Real-time Detection of Circulating Melanoma Cells", 
        "overall_contact": {
            "email": "HutchinsLauraF@uams.edu", 
            "last_name": "Laura Hutchins, MD", 
            "phone": "501-686-8530"
        }, 
        "overall_official": {
            "affiliation": "University of Arkansas", 
            "last_name": "Laura Hutchins, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of participants that possess circulating tumor cells.", 
            "safety_issue": "No", 
            "time_frame": "14-21 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01776905"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "University of Arkansas", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Arkansas", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}